An oligomeric compound for use in therapy, said compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides, wherein the modified oligonucleotide has a modification motif comprising: a 5'-region consisting of 2-8 linked 5'-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 5'-region nucleoside is a modified nucleoside; wherein at least one modified 5'-region nucleoside comprising a modified sugar; and wherein the 3'-most 5'-region nucleoside is a modified nucleoside; a 3'-region consisting of 2-8 linked 3'-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 3'-region nucleoside is a modified nucleoside; wherein at least one modified 3'-region nucleoside comprising a modified sugar; and wherein the 5'-most 3'-region nucleoside is a modified nucleoside; and a central region between the 5'-region and the 3'-region consisting of 6-10 linked central region nucleosides, each independently selected from among: a modified nucleoside and an unmodified deoxynucleoside, wherein the 5'-most central region nucleoside is an unmodified deoxynucleoside and the 3'-most central region nucleoside is an unmodified deoxynucleoside; wherein one or two central region nucleosides are modified nucleosides and each of the other central region nucleosides is an unmodified deoxynucleoside; wherein 5-methyl cytosine is not a modified nucleobase; wherein the modified oligonucleotide has a nucleobase sequence complementary to the nucleobase sequence of a target region of a target nucleic acid; wherein the nucleobase sequence of the target region of the target nucleic acid differs from the nucleobase sequence of at least one non-target nucleic acid by a single differentiating nucleobase; wherein the single differentiating nucleobase is a single-nucleotide polymorphism; wherein the single nucleotide polymorphism is associated with disease; wherein the oligomeric compound is an antisense oligomeric compound; wherein the antisense compound results in RNase H mediated cleavage of the target nucleic acid, said cleavage providing said therapy; wherein the target nucleic acid is an endogenous RNA molecule; wherein the target RNA is associated with a disease or disorder; and wherein at least one modified 3'-region nucleoside comprises a bicyclic sugar moiety. a 5'-region consisting of 2-8 linked 5'-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 5'-region nucleoside is a modified nucleoside; wherein at least one modified 5'-region nucleoside comprising a modified sugar; and wherein the 3'-most 5'-region nucleoside is a modified nucleoside; a 3'-region consisting of 2-8 linked 3'-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 3'-region nucleoside is a modified nucleoside; wherein at least one modified 3'-region nucleoside comprising a modified sugar; and wherein the 5'-most 3'-region nucleoside is a modified nucleoside; and a central region between the 5'-region and the 3'-region consisting of 6-10 linked central region nucleosides, each independently selected from among: a modified nucleoside and an unmodified deoxynucleoside, wherein the 5'-most central region nucleoside is an unmodified deoxynucleoside and the 3'-most central region nucleoside is an unmodified deoxynucleoside; wherein one or two central region nucleosides are modified nucleosides and each of the other central region nucleosides is an unmodified deoxynucleoside; wherein 5-methyl cytosine is not a modified nucleobase; wherein the modified oligonucleotide has a nucleobase sequence complementary to the nucleobase sequence of a target region of a target nucleic acid; wherein the nucleobase sequence of the target region of the target nucleic acid differs from the nucleobase sequence of at least one non-target nucleic acid by a single differentiating nucleobase; wherein the single differentiating nucleobase is a single-nucleotide polymorphism; wherein the single nucleotide polymorphism is associated with disease; wherein the oligomeric compound is an antisense oligomeric compound; wherein the antisense compound results in RNase H mediated cleavage of the target nucleic acid, said cleavage providing said therapy; wherein the target nucleic acid is an endogenous RNA molecule; wherein the target RNA is associated with a disease or disorder; and wherein at least one modified 3'-region nucleoside comprises a bicyclic sugar moiety.